Inactive Instrument

Trillium Therapeutics

TRIL

CA89620X5064

Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P Global BMI Index

November 19, 2021 at 12:00 am EST

Latest news about Trillium Therapeutics

TCR2 Therapeutics Appoints Chief Business and Strategy Officer	22-01-12	MT
Pfizer Deploying Some of Its Covid Cash in Arena Deal -- Analysis	21-12-13	DJ
Pfizer Eyes Enhanced Immuno-Inflammatory Disease Expertise With $6.7 Billion Arena Pharmaceuticals Takeover	21-12-13	MT
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P Global BMI Index	21-11-19	CI
Pfizer Completes $2.22 Billion Trillium Therapeutics Acquisition	21-11-17	MT
Trillium Therapeutics Inc. Announces Executive Changes	21-11-17	CI
Trillium Therapeutics Inc. Announces Resignation of Jan Skvarka as Chief Executive Officer	21-11-17	CI
Trillium Therapeutics Inc. Announces Cessation of James Parsons as Chief Financial Officer	21-11-17	CI
Benchmark Downgrades Trillium Therapeutics to Hold From Buy	21-11-17	MT
Pfizer-Trillium Therapeutics $2.26 Billion Deal Secures Canada, US Approval	21-11-17	MT
Trillium Therapeutics Inc.(NasdaqCM:TRIL) dropped from NASDAQ Composite Index	21-11-17	CI
Pfizer Inc. completed the acquisition of remaining 97.8% stake in Trillium Therapeutics Inc. from New Enterprise Associates 16, L.P., a fund managed by New Enterprise Associates, Inc., Avoro Capital Advisors LLC, RA Capital Healthcare Fund, L.P., a fund managed by RA Capital Management, L.P. and others.	21-11-16	CI
Trillium Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
North American Morning Briefing : Stock Futures -3-	21-11-05	DJ
Trillium Therapeutics Brief: Says Received Final Court Order Approving Arrangement With PF Argentum ULC, a wholly-owned, indirect subsidiary of Pfizer Inc	21-10-28	MT
Trillium Therapeutics Brief: Securityholders Approve Acquisition by Pfizer	21-10-26	MT
Transcript : Trillium Therapeutics Inc. - Shareholder/Analyst Call	21-10-26
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P/TSX Composite Index	21-09-20	CI
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P/TSX Completion Index	21-09-20	CI
Trillium Therapeutics Inc.(TSX:TRIL) dropped from S&P/TSX Capped Composite Index	21-09-20	CI
Health Care Up Amid Deal Activity -- Health Care Roundup	21-08-30	DJ
TRILLIUM THERAPEUTICS : Benchmark Adjusts Price Target for Trillium Therapeutics to C$23.34 From C$26.41, Maintains Buy Rating	21-08-24	MT
Trackinsight: Rising oil and gold prices propel Canadian shares	21-08-24	TI
Today on Wall Street: A new central bank theory	21-08-24
TRILLIUM THERAPEUTICS : Craig-Hallum Downgrades Trillium Therapeutics to Hold From Buy	21-08-24	MT

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company. The Company is engaged in developing therapies for the treatment of cancer. The Company is developing two clinical programs, TTI-621 and TTI-622, target CD47, a don?t eat me signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. The TTI-621 is being evaluated in a multicenter, open-label phase I trial in patients with relapsed/refractory hematologic malignancies. The TTI-622 is Trillium's second SIRP?Fc fusion protein. TTI-622 consists of the same extracellular CD47-binding domain of human SIRP? as TTI-621 but has an immunoglobulin G4 (IgG4) Fc region instead of an IgG1 Fc. TTI-622 is being studied in a two-part, multicenter, open-label, phase Ia/Ib study in patients with advanced relapsed or refractory lymphoma or multiple myeloma (NCT03530683). It focuses on developing inhibitors of CD47, a checkpoint of the innate immune system.

Sector

More about the company